Shanghai Yizhong Pharmaceutical Co.Ltd(688091) planned to expand the clinical trials of paclitaxel polymer micelles for injection against breast cancer, small cell lung cancer and other cancers

Shanghai Yizhong Pharmaceutical Co.Ltd(688091) announced that the cumulative deviation of the closing price of the company’s stock trading within 10 consecutive trading days has reached 100%, which belongs to the situation of serious abnormal fluctuation of stock trading. The company’s core product paclitaxel polymer micelles for injection was approved in October 2021, and the product is still in the early stage of listing. Clinical research data show that although this product has its unique advantages and progressiveness in the first-line treatment of advanced non-small cell lung cancer (NSCLC) compared with other marketed paclitaxel formulations, it still faces the possibility that the market does not meet expectations. The company has been actively planning the clinical trials of expanded indications of paclitaxel polymer micelles for injection against breast cancer, small cell lung cancer and other cancers. In the future, the company will increase R & D expenditure, which will have a certain impact on profits.